Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 7/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.49 |
| ▸ | NMT1 | P30419 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16481857 | 0.97 | HCRTR1 (0.49) | HCRTR1HCRTR2NMT1KDM4EGAA | |
| SCHEMBL17068998 | 0.95 | HCRTR1 (0.46) | HCRTR1HCRTR2NMT1KDM4EGAA | |
| SCHEMBL16482009 | 0.79 | HSD17B10 (0.58) | KDM4EGAAMAPTNPSR1HSD17B10 | |
| SCHEMBL16481855 | 0.77 | HSD17B10 (0.46) | HCRTR1HCRTR2KDM4EGAAMAPT | |
| SCHEMBL16067416 | 0.77 | HSD17B10 (0.55) | HCRTR1HCRTR2KDM4EGAAMAPT | |
| SCHEMBL16481943 | 0.76 | HSD17B10 (0.45) | HCRTR1HCRTR2KDM4EGAAMAPT | |
| SCHEMBL16481889 | 0.74 | L3MBTL1 (0.47) | KDM4EGAAMAPTNPSR1HSD17B10 | |
| SCHEMBL13197572 | 0.73 | L3MBTL1 (0.49) | KDM4EGAAMAPTNPSR1HSD17B10 | |
| SCHEMBL29640815 | 0.70 | S1PR1 (0.46) | KDM4EGAAMAPTNPSR1HSD17B10 | |
| SCHEMBL13141488 | 0.69 | RAB9A (0.47) | NMT1MAPTFFAR4ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| WO-2014141065-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014057435-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO )ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | HCRTR1 2/4885HCRTR2 1/4885NMT1 3668/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885NMT1 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.